GLSI Projected Dividend Yield
Greenwich LifeSciences Inc ( NASDAQ : GLSI )Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Co.'s product candidates include GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers; and granulocyte macrophage colony-stimulating factor immunoadjuvant, which is to improve monocyte and neutrophil cytotoxicity against melanoma tumor cells and to improve activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies. 20 YEAR PERFORMANCE RESULTS |
GLSI Dividend History Detail GLSI Dividend News GLSI Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |